EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu
EyePoint shares plummet after phase 3 stumble for AMD drug-device combo Duravyu Fierce Pharma
Covered in this story
What has happened since
- Advanced Micro Devices is up 0.4% since this was published, 66 days ago.
- Eyepoint Inc is down 91.2% since this was published, 66 days ago.
Price move measured from the close nearest publication to the latest quote.
Analyst targets on Advanced Micro Devices
- Bank of America: $606 → $720 by Oct 2027 · Buy via FXLeaders
- UBS: $608 → $700 by Oct 2027 · Buy via Stocktwits
- Rosenblatt Securities: $608 → $665 by Oct 2027 · Buy via Stocktwits
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $AMD yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Advanced Micro Devices →Dalsna Finance is currently tracking 55 stories mentioning Advanced Micro Devices, the earliest published 4 Aug 2026.
Summary aggregated from Fierce Pharma's public RSS feed. The full reporting belongs to Fierce Pharma — please read it on their site.